Control of IGF-I Levels with Lanreotide Autogel in Acromegaly Patients
Author Information
Author(s): Philippe Chanson, Françoise Borson-Chazot, Jean-Marc Kuhn, Joëlle Blumberg, Pascal Maisonobe, Brigitte Delemer, the Lanreotide Acromegaly Study Group
Primary Institution: Université Paris-Sud 11 and Assistance Publique-Hôpitaux de Paris
Hypothesis
The study aims to assess the efficacy and safety of 48 weeks of titrated dosing of lanreotide Autogel in patients with acromegaly.
Conclusion
The treatment effectively controlled IGF-I and GH levels, reduced acromegaly symptoms, and was well tolerated.
Supporting Evidence
- 43% of patients achieved normalized IGF-I levels by the end of the study.
- 85% of patients had GH levels ≤ 2.5 µg/l at study end.
- Acromegaly symptoms significantly reduced in most patients throughout the study.
- The most common adverse events were gastrointestinal, as expected for somatostatin analogues.
Takeaway
This study shows that a medicine called lanreotide can help people with a condition called acromegaly feel better by lowering certain hormone levels.
Methodology
Patients received 12 injections of lanreotide Autogel at 28-day intervals, with dose adjustments based on GH and IGF-I levels.
Potential Biases
Potential bias due to the open-label design and lack of a control group.
Limitations
The study was open-label and conducted at multiple centers, which may introduce variability.
Participant Demographics
{"mean_age":55.3,"sex_distribution":{"male":60,"female":40},"previous_treatments":{"pituitary_surgery":59,"pituitary_radiotherapy":19,"medical_treatment":78}}
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 31–55
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website